TIL
Instil Bio, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Jan 7 ▼ HC Wainwright & Co. downgrades
- Nov 16 New catalyst: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q3 2026: 3 added (0 new), 2 trimmed or exited.
- Short sellersSTEADY
Short interest +6.3% to 181.2K shares. 2.3 days to cover, ≈2.7% of shares.
- TrendRANGE
14% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| UBS Group AG | ADD | $1.7M |
| VANGUARD FIDUCIARY TRUST CO | ADD | $213.5K |
| MORGAN STANLEY | ADD | $137.5K |
| BARCLAYS PLC | NEAR_EXIT | $14.00 |
| UBS Group AG | DOUBLED | $1.4M |
| MORGAN STANLEY | TRIM | $91.8K |
| BARCLAYS PLC | NEAR_EXIT | $223.00 |
| MILLENNIUM MANAGEMENT LLC | TRIM | $1.1M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Jan 2026| Date | Firm | Rating |
|---|---|---|
| Jan 7, 2026 | HC Wainwright & Co. DOWNGRADE | Neutral |
| Sep 11, 2025 | HC Wainwright & Co. REITERATE | Buy |
| Aug 27, 2025 | HC Wainwright & Co. REITERATE | Buy |
| Aug 15, 2025 | HC Wainwright & Co. REITERATE | Buy |
| Jun 5, 2025 | HC Wainwright & Co. REITERATE | Buy |
| Jun 2, 2025 | JMP Securities REITERATE | Market Perform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Binder Gwendolyn Director Jun 11, 2026 | AWARD | 6,500 sh |
Gibson Neil W Director Jun 11, 2026 | AWARD | 0 sh |
Matcham George Director Jun 11, 2026 | AWARD | 6,500 sh |
McGaughy R Kent Jr Director Jun 11, 2026 | AWARD | 6,500 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | None | None | No data | $0.00 |
Short side
FINRA· Oct 30, 2026SecBot reports
7 filings · 1 press release · 0 bullish · 0 bearish · 7 neutral- NEUTRAL 8-KNov 16, 2026
Instil Bio reported Q3 2026 net loss of $4.2M ($0.62 per share), narrower than the $13.6M loss in Q3 2025, as operating expenses continued to decline sharply. Cash and investments totaled $67.1M at quarter end, expected to fund operations through 2027.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL PRESS-RELEASEAug 13, 2026
Instil Bio reported Q2 2026 GAAP net loss of $0.63 per share, narrowing from a $3.24 loss in Q2…
Monitor for any announcement of a potential acquisition or in-licensing deal, as the company's stated strategy and cash position suggest a transaction is the primary catalyst. Absent a deal, the…
- NEUTRAL 8-KAug 13, 2026
Instil Bio reported Q2 2026 results with a GAAP net loss of $0.63 per share, narrowing from a…
Monitor for any definitive agreement on an acquisition or in-licensing transaction, which would be the primary catalyst for this stock. Absent a deal, the stock is likely to trade on cash runway and…
- NEUTRAL 8-KMay 15, 2026
Instil Bio reported Q1 2026 GAAP EPS of -$0.62, a slight miss vs consensus -$0.59, but as a…
No material event; stock likely to trade on broader biotech sentiment and M&A speculation. Watch for any definitive acquisition agreement or pipeline update as the next catalyst.
All TIL filing & press-release reports (8)
- 8-K reportNov 16, 2026
- PRESS-RELEASE reportAug 13, 2026
- 8-K reportAug 13, 2026
- 8-K reportMay 15, 2026
- PRESS-RELEASE reportMay 15, 2026
- DEFA14A reportApr 24, 2026
- 8-K reportApr 3, 2026
- PRESS-RELEASE reportMar 27, 2026